SEATTLE — Davorka Tomic, head of clinical development in neurology at Merck KGaA, spoke with Healio at the 2022 American Academy of Neurology annual meeting about multiple clinical trials for patients with MS.
In a phase 2 trial, a twice-daily 75 mg dose of evobrutinib showed sustained efficacy at 244 weeks, she said, as well as good long-term safety. Another study showed a clinical effect on the volume of brain lesions in patients with MS.
SEATTLE — Davorka Tomic, head of clinical development in neurology at Merck KGaA, spoke with Healio at the 2022 American Academy of Neurology annual meeting about multiple clinical trials for patients with MS.
In a phase 2 trial, a twice-daily 75 mg dose of evobrutinib showed sustained efficacy at 244 weeks, she said, as well as good long-term safety. Another study showed a clinical effect on the volume of brain lesions in patients with MS.
